DoW Duchenne Muscular Dystrophy, Idea Development Award

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. <strong><em>The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.</em></strong></p><p><br></p><p><strong><em>Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:</em></strong></p><p>• The <u>Established Investigator</u> category is for independent investigators at all academic levels, or equivalent</p><p><br></p><p>• The <u>New Investigator – Early-Stage</u> category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.</p><p><br></p><p>• The <u>New Investigator – Transitioning</u> category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.</p><p><br></p><p>Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are <strong><em>required </em></strong>for all applications. Clinical trials or clinical trial aims are not allowed.</p>